We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » FDA Issues Guidance on Charging for IND Drugs, Expanded Access
FDA Issues Guidance on Charging for IND Drugs, Expanded Access
May 22, 2013
Companies that want to charge patients for an investigational drug during a clinical trial must prove to the FDA that the trial could not otherwise be conducted “because the cost of the drug is extraordinary,” according to a draft guidance.